Navigation Links
SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
Date:5/13/2008

development and commercialization, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to file INDs or commence IND enabling activities or preclinical or clinical studies in the referenced time frames. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or future clinical trials. In addition, results may be affected by the initiation, implementation and conclusion of its collaborations, cash generated or used in connection with new or existing collaborations, the failure to successfully complete collaborations or partnerships or enter into new collaborations on any of its research and development programs, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, the level of resources that its collaborative partners devote to development of its product candidates, the scope and validity of patent protection for its products, and its ability to obtain additional funding to support its operations. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10- K for the year ended December 31, 2007, as well as other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances after the dat
'/>"/>
SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... According to Jeff Howell, Partner of Nidea ... new development in Downtown Toronto is expanding at a ... 755 storeys of new development last week (including three ... dominating the Toronto skyline for the foreseeable future in ... for new development. , As the Toronto city council ...
(Date:9/15/2014)... 16, 2014 Cancer Immunotherapy ... Adoptive T-cell Therapies is a new market research ... the three principal types of therapeutics that have ... in cancer immunotherapy (which is often called "immuno-oncology") ... and Adoptive cellular immunotherapy. , The regular ...
(Date:9/15/2014)... fast when a patient has sepsis, a life-threatening condition ... blood -- often too fast for antibiotics to help. ... developed by a team at Harvard,s Wyss Institute for ... treat sepsis. , "Even with the best current ... at least 30 percent of the time," said Mike ...
(Date:9/15/2014)... , Sept. 15, 2014 Zymo ... viral transport solution for safe ambient temperature storage ... molecular testing. Importantly, the infectivity of agents in such ... maintaining the integrity of the viral nucleic acids ... the recent Ebola epidemic in West ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3
... Dr. ... San Antonio and South Central Texas, , ... (PRWEB) June 15, 2010 -- For those looking for a trimmer physique without ... Zeltiq ™ Procedure, a new non-invasive body contouring procedure, at his practice - Advanced ...
... data from a retrospective cohort study showed that up to three quarters ... have a substantial adverse effect on major PD-related clinical and health economic ... Disease and Movement Disorders in Buenos Aires, Argentina ( June ... , "The ...
... leading publication on diversity and business, has recognized University Hospitals as a leader among ... , , ... Companies for Diversity based on results from an extensive questionnaire. This is the first ... , , ...
Cached Biology Technology:Dr. Suresh Koneru Introduces Zeltiq Non-Invasive Procedure For Fat Reduction 2Dr. Suresh Koneru Introduces Zeltiq Non-Invasive Procedure For Fat Reduction 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 2New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 4Diversity Publication Names University Hospitals One of Top Hospital Systems in the Nation 2
(Date:9/15/2014)... 2014) The so-called central dogma of molecular ... provided a simplified explanation for how genetic information ... , In reality, of course, the process is ... nearly 60 years ago by Nobel Laureate Francis ... one, there are multiple types of RNA, three ...
(Date:9/15/2014)... a simple, mechanical solution to avoid chromosome sorting ... Science Express. , This natural ... lead to infertility, miscarriage, or congenital conditions. ... problems, but what exactly goes wrong is often ... Trust Center for Cell Biology at the University ...
(Date:9/15/2014)... that a single group of microorganisms may be responsible ... the oceans, with implications for the global carbon cycle ... essential molecule required by most life on this planet, ... of microorganisms because it is so large and complex. ... maintaining the brain and nervous systems, as well as ...
Breaking Biology News(10 mins):Scientists discover RNA modifications in some unexpected places 2Cells simply avoid chromosome confusion 2Cells simply avoid chromosome confusion 3Researchers discover new producer of crucial vitamin 2
... University of North Carolina at Chapel Hill has received ... & Melinda Gates Foundation. The grant will support ... Tsuruta, PhD, and Paul Dayton, PhD, titled "Ultrasound as ... professor in the Laboratories for Reproductive Biology in UNC,s ...
... It has been a hard winter for Monarch butterflies, according ... of Kansas. Taylor said that low temperatures, storms and habitat ... "I spend a lot of time fretting over ... for factors or data that will help me understand the ...
... team of researchers led by University of Notre Dame ... thinking about the genomics of speciation. Titled "Widespread genomic ... edition of the Proceedings of the National Academy ... how the genomes of newly forming species should differ ...
Cached Biology News:UNC researchers receive $100,000 Grand Challenges Exploration Grant to develop male contraceptive 2As monarch butterflies journey north, gardeners can help protect species, researcher says 2Paper offers new insights into the genomics of speciation 2
Spastin (Sp 3G11/1)...
mCD-1 10 transcription reactions...
... Rabbits x 2 , ... bleed x1 /each , Immunizations/Boost injections ... (app. 5 ml) x1 /each , ... /each , Final Bleed ~ 100 ml blood ...
Mouse VCAM-1/CD106 MAb (Clone 112702)...
Biology Products: